Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
49 hedge funds and large institutions have $100M invested in Regulus Therapeutics in 2014 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 18 increasing their positions, 14 reducing their positions, and 8 closing their positions.
5,600% more call options, than puts
Call options by funds: $57K | Put options by funds: $1K
95% more capital inflows, than outflows
Capital inflows: $4.05M | Capital outflows: $2.08M
29% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 14
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.92% less ownership
Funds ownership: 32.91% → 29.99% (-2.9%)
8% less funds holding
Funds holding: 53 → 49 (-4)
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.35M |
| 2 |
Schroder Investment Management Group
London,
United Kingdom
|
+$1.01M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$781K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$245K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$206K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Tocqueville Asset Management
New York
|
-$551K |
| 2 |
BlackRock Institutional Trust
San Francisco,
California
|
-$349K |
| 3 |
Goldman Sachs
New York
|
-$207K |
| 4 |
BlackRock Advisors
Wilmington,
Delaware
|
-$162K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$145K |
RGLS Hedge Fund Activity: Q3 2014 in Review
49 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q3 2014, worth a combined $100M — down 13% from $115M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of RGLS and 4 opened new positions — a net loss of 4 holders — while 14 trimmed existing stakes and 18 added.
The largest buyer was Fidelity Investments, adding an estimated $1.35M. The largest seller was Tocqueville Asset Management, exiting entirely with an estimated $551K sold.
- 49 institutional investors held Regulus Therapeutics (RGLS) as of Q3 2014, down from 53 in Q2 2014.
- Funds reported $100M of Regulus Therapeutics stock for Q3 2014, down 13% quarter-over-quarter.
- 4 funds opened new Regulus Therapeutics positions in Q3 2014 and 8 closed out, a net change of -4 holders.
- The largest Regulus Therapeutics buyer in Q3 2014 was Fidelity Investments, an estimated $1.35M added.
- The largest Regulus Therapeutics seller in Q3 2014 was Tocqueville Asset Management, an estimated $551K sold.
Based on aggregated 13F filings for Q3 2014.